aTYR PHARMA (ATYR) Net Equity Issued and Repurchased (2014 - 2025)

aTYR PHARMA (ATYR) has reported Net Equity Issued and Repurchased for 12 consecutive years, with $29.7 million the latest figure, recorded in Q3 2025.

• For the quarter ending Q3 2025, Net Equity Issued and Repurchased rose 29600.0% year-over-year to $29.7 million; the trailing twelve-month figure through Dec 2025 stood at $66.4 million (up 69.35% YoY), and the FY2025 full-year result was $66.4 million, up 64.76% from the prior year.
• Net Equity Issued and Repurchased advanced to $29.7 million in Q3 2025 per ATYR's latest filing, from $17.9 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $65.4 million in Q3 2021 and bottomed at -$65.4 million in Q4 2021.
• Historically, Net Equity Issued and Repurchased has averaged $8.4 million across 5 years, with a median of $6.1 million in 2023.
• The sharpest annual moves came in 2021 and 2025: Net Equity Issued and Repurchased sank 1776.92% in 2021, then surged 218504.65% in 2025.
• Over 5 years, Net Equity Issued and Repurchased stood at -$65.4 million in 2021, then jumped by 101.38% to $900000.0 in 2022, then surged by 577.78% to $6.1 million in 2023, then soared by 209.84% to $18.9 million in 2024, then surged by 57.14% to $29.7 million in 2025.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $29.7 million, $17.9 million, and $18.8 million for Q3 2025, Q2 2025, and Q1 2025 respectively.